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nant), Plasma/Albumin-Free Method (rAHF-PFM), was devel-
oped as an alternative treatment option for patients with hemo-
philia A. However, there is concern that this new technology
contributes signiﬁcant cost to the health care of these patients.
This model was developed to delineate the economic impact of
rAHF-PFM on a health care plan’s budget. METHODS: Payer
perspective is utilized for the analysis under a one-year time
horizon. The economic impact of the introduction of rAHF-PFM
was determined using average wholesale price. Estimates of
hemophilia A prevalence, factor VIII utilization, treatment regi-
mens, and clinical outcomes were derived from published litera-
ture. Migration from previous therapies (i.e., Helixate,
Kogenate, Recombinate, ReFacto, pdFVIII) to rAHF-PFM (17%
of patients) was based on equivalent market shares. Numerous
sensitivity analyses were performed to demonstrate the robust-
ness of the ﬁndings. RESULTS: In a 1,000,000 member plan, fol-
lowing introduction of rAHF-PFM, with 82.5% on-demand use
(30IU/kg/bleed with 16.8 bleeds/year) and 17.5% prophylactic
use (60IU/kg/week with 6.6 bleeds/year), it is estimated that
overall annual factor VIII treatment cost is $3,835,191, an
annual increase of $39,268 ($0.003 per member per month
increase). CONCLUSIONS: While there is heightened concern
regarding the potential budget impact of new technologies in
health care, this model demonstrates that rAHF-PFM can be pro-
vided to patients with relatively modest impact on a health care
plan’s budget.
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OBJECTIVES: While treatment options for hemophilia A have
provided effective disease management and have greatly
increased life expectancy, the Medical and Scientiﬁc Advisory
Council (MASAC) of the National Hemophilia Foundation has
recommended that “all efforts should be made to remove human
albumin from recombinant factor VIII products” to obviate lin-
gering concerns regarding the potential for viral transmission
through the use of factor VIII concentrates. To delineate the eco-
nomic value of a plasma/albumin-free factor VIII product, the
ﬁscal impact attributable to such a product was determined
under assumed emergence of a novel infectious blood/plasma
borne virus. METHODS: A deterministic model was developed
incorporating age-adjusted and proportionally weighted median
present-value (1999) annual expense estimates for the manage-
ment of HIV and AIDS for males, proportion of the hemophilia
A population infected due to the emergence of a novel blood
(plasma) borne virus (5%), fractional expense of that observed
with HIV/AIDS (5%), and the number of bleeding events expe-
rience by a given individual per year (i.e., international units of
factor VIII administered). Analyses were conducted for individ-
uals weighing 20-, 50-, and 80-kg. RESULTS: Under the assump-
tion of the emergence of a novel infectious blood (plasma) borne
virus, the model revealed a savings potential (p < 0.05) with the
use of a plasma/albumin-free factor VIII product relative to use
of a plasma/albumin-containing product, ranging from $0.06 per
IU (80kg male, 12 bleeding episodes/year) to $0.48 per IU 
(20kg male, 6 bleeding episodes/year), equating to a potential
cost-avoidance of $1742 to $6967 per year (present value).
CONCLUSIONS: Antihemophilic Factor (recombinant),
Plasma/Albumin-Free Method (rAHF-PFM) offers hemophilia A
patients a treatment regimen meeting MASAC recommendations
which eliminates the risk of infection from human and animal
protein additives with potential economic savings stemming
from avoidance of future costs associated with infections trans-
mitted through factor replacement therapy.
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OBJECTIVE: The residual risk of transmitting current and
emerging infectious blood-borne pathogens via blood transfu-
sion persists despite recent blood safety advances. The INTER-
CEPT Blood System (IBS) for platelets has been developed to
further reduce these pathogen transmission risks during platelet
transfusions. The objective of this study was to assess the cost-
effectiveness of using single-donor (aphaeresis) platelets (SDP)
processed with IBS in Japan. METHODS: A literature-based
decision analysis model was used to assess the cost-effectiveness
of the IBS in four patient populations that account for most of
the platelet usage in Japan: 1) a 10-year old male with acute lym-
phocytic leukaemia (ALL); 2) a 50-year old male with non-
Hodgkin’s lymphoma (NHL); 3) a 60-year old male undergoing
heart bypass surgery (CABG); and 4) a 70-year old female under-
going a hip arthroplasty. Pathogen exposure included HIV, HCV,
HBV, HTLV-I, bacterial sepsis, emerging and migrating
pathogens. The model compared projected quality-adjusted life-
year saved (QALY) and costs for patients receiving untreated vs.
treated platelets. RESULTS: The incremental cost per QALY
gained by using SDP + IBS vs. SDP ranged from
¥96,248,673–¥793,899,885. Inclusion of a hepatitis C-like
emerging pathogen beneﬁt signiﬁcantly improved the cost effec-
tiveness to ¥20,534,864–¥434,648,944. The model was most
sensitive to mortality from bacterial contamination and the risk
rate of emerging and/or migrating pathogens. The model was rel-
atively insensitive to transmission risks from currently known
viruses. CONCLUSION: The cost-effectiveness of IBS for
platelets is comparable and mostly better to that of other blood
and general safety interventions (e.g., mini-pool NAT testing,
chemical regulations, trafﬁc safety measures) that are accepted
as valuable in Japan. Thus, pathogen inactivation with IBS may
be considered as a desirable strategy to further improve the safety
of platelet transfusions and a valuable insurance against the
threat of new emerging and migrating pathogens.
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OBJECTIVES: Extended prophylaxis with the synthetic pen-
tasaccharide fondaparinux for one month versus one week in hip
fracture surgery has been shown to reduce the risk of venous
thromboembolism (VTE) by 96% in the Penthifra Plus trial. The
cost-effectiveness of extended prophylaxis with fondaparinux
from a Swiss perspective still remains to be determined.
METHODS: We developed a decision analytic cost-effectiveness
model comparing the use of fondaparinux for four weeks versus
one week from a health care perspective. The analyses were per-
formed for patients undergoing hip fracture surgery (HFS) and
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total hip replacement (THR) separately. Efﬁcacy data were
extracted from published randomised controlled trials. Cost data
were derived from the literature and other published sources and
natural history data after VTE from observational studies. Costs
were expressed in 2003 Swiss Francs (CHF) and effects as life-
years gained (LYG). Deterministic sensitivity analysis was used
to assess the robustness of the model. RESULTS: In patients
undergoing HFS, the incremental cost-effectiveness ratio (ICER)
of extended fondaparninux prophylaxis versus a one-week
regimen was CHF 2920/LYG after 30 days, with cost-savings
reached after 5 years. In patients undergoing THR, the ICER of
extended fondaparninux prophylaxis versus a 1-week regimen
was CHF 21183/LYG after 30 days, with cost-savings reached
after 5 years. CCONCLUSIONS: Within the limitations of the
model, extended prophylaxis with fondaparinux is cost-effective
for the prevention VTE in major orthopaedic surgery in 
Switzerland.
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OBJECTIVES: ISAM, a multicenter, observational, retrospec-
tive, cross-sectional study, aimed at describing the anticoagula-
tion treatment monitoring on patients with chronic non-valvular
atrial ﬁbrillation (CNVAF), receiving Oral Anticoagulation
Therapy (OAT) for stroke prophylaxis, (follow-up Jan-Dec
2002); and estimating direct and indirect costs in the Italian
National Health System perspective. METHODS: Seven out of
8 Anti-Coagulation Clinics (ACC’s), selected to represent the
whole Italian territory, enrolled 23 randomized patients with
CNVAF. RESULTS: The total number of patients was 177 :102
males and 75 females (mean age 72 years); 90% with chronic
Atrial Fibrillation and 10% with paroxysmal; 77% subjects
received warfarin and 23% acenocumarol. Forty percent of all
tests required dosage changes and the mean interval between two
consecutive tests was 20 days. The quality of OAT monitoring,
according to Rosendaal’s analysis, was: 67.9% of time spent in
the range 2.0–3.0, 21% below and 10% above this range. Unit
costs, using National tariffs were: 5.16€ and 12.91€ for INR 
tests and visits respectively, retail price for drugs (warfarin:
0.0145€/mg; acenocumarol: 0.0095€/mg) and appropriate DRG
tariffs for admissions. Total cost per patient per year was 943€:
745€ direct costs and 198€ indirect ones. Medical costs, 525€,
included OAT drug (5%), INR tests (18%), monitoring visits
(44%) and admissions (33%); non-medical costs (transporta-
tion) amounted to 220€. CONCLUSIONS: Patients in ACC
management could obtain good level of INR control: Time in
Target Range (TTR) 67.9%. ISAM is a ﬁrst attempt to assess
cost of OAT monitoring in Italy, conﬁrming that AF is a growing
health problem, as well as a cause of health costs that includes
drugs, INR tests and monitoring visits, which are the most deter-
minant in the total costs. In addiction, indirect costs (productiv-
ity loss by patients or their caregivers) were 21% of total costs.
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OBJECTIVES: To evaluate the preferences of physicians and
pharmacists toward products used for replacement therapy.
METHODS: This study investigates preferences on hemophilia
care in 69 physicians and 58 pharmacists using conjoint analy-
sis, a technique for establishing the relative importance of dif-
ferent characteristics in the provision of a good or service.
Attributes and levels were: perceived viral safety (as that pro-
vided by highly puriﬁed double inactivation plasma derived
versus recombinant concentrates), risk of inhibitor development
(1/4, 1/6, 1/10 PUP’s), factor infusion frequency on prophylaxis
(thrice, twice, once a week), pharmaceutical dosage form
(lyophilized material or a ready-to-use solution), way of distrib-
ution (home, ofﬁce pharmacy, hospital) and price. RESULTS:
Excluding pharmaceutical dosage form for physicians and ofﬁce
pharmacy delivery for pharmacists, all attributes considered
tested important to respondents. Physicians showed a strong
preference toward both outcome variables (viral safety, risk of
development of inhibitors) and process variables (distribution,
infusion frequency) while pharmacists showed a strong prefer-
ence only for outcome variables and unexpectedly not toward
way of distribution. CONCLUSIONS: Our study is the ﬁrst to
apply conjoint analysis to establish preferences of physicians and
pharmacists in hemophilia replacement therapy. This study pro-
vided evidence of the usefulness of conjoint analysis in plan
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